Pan-Cancer Analysis of Enhancer-Induced PAN3-AS1 and Experimental Validation as a WFDC13-Promoting Factor in Colon Cancer
In short, PAN3-AS1 is a valuable biomarker for diagnosis and prognosis. PAN3-AS1 exhibits linkage to a cold tumor immune microenvironment (TME) and forecasts durable benefit from immunotherapy. Addressing the PAN3-AS1/miR-423-5p/WFDC13 axis might provide a novel option for improving immunotherapy efficacy in colon cancer.
Authors
- Ying Cai (ORCID: https://orcid.org/0009-0005-1223-6365)
- Yanan Yu (ORCID: https://orcid.org/0000-0002-8143-6978)
- Xiaolin Ma (ORCID: https://orcid.org/0000-0002-9762-1668)
- Xu Guo (ORCID: https://orcid.org/0000-0003-4902-8859)
Institutions
- Weifang Medical University (CN)
- Zhejiang Hospital (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-11-14
- DOI
- https://doi.org/10.32604/or.2025.069274
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00